Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.64 per share a year ago.

Iovance Biotherapeutics (IOVA) Reports Q4 Loss, Misses Revenue Estimates

Iovance Biotherapeutics, Inc. (IOVA) Q4 2023 Earnings Call Transcript

Amtagvi™ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer

Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Iovance (IOVA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Iovance (IOVA) Might Surprise This Earnings Season

Instacart (Maplebear Inc.)

Exelixis

Gates Industrial

Prime Medicine Inc

Public offerings of stock tempted some insiders, including a chief executive, to increase their stakes in a couple of biotechs and an industrial products maker.

Stock Offerings Prompt Big Insider Buying

Agree Realty

Intel

One of the best ways to spot potential opportunities is by paying close attention to insider buying stocks. After all, it's the insiders, such as the CEOs, CFOs and directors, that know their company the best.

3 Stocks Flashing Recent Insider Buying Signals

Axsome Therapeutics

Immunovant Inc

The biotech sector is in the spotlight in 2024, where under-the-radar biotech stocks with upcoming catalysts could offer significant upside. Analysts are projecting an acceleration in new drug approvals as demand for effective treatments for chronic diseases continues to increase.

3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024

Iovance Biotherapeutics earned approval for its first new drug, Amtagvi, on Feb. 16. Amtagvi is a first-in-class treatment that uses a patient's own immune cells to attack solid tumors.

1 Soaring Growth Stock That Could Rise Another 53%, According to Wall Street

Iovance shares have surged more than 70% in just a few days. The gains came after the biotech won approval for its very first product, one that relies on the body's own cells.

Is Iovance a Buy After Its First Regulatory Win?

Iovance Biotherapeutics is now launching its first cell therapy drug. That's prompting financial analysts to adjust their price targets.

This Biotech Stock Has 47% Upside, According to 1 Wall Street Analyst

Ginkgo Bioworks Holdings

Analysts are bullish, on average, regarding both Ginkgo Bioworks and Iovance Biotherapeutics. Ginkgo Bioworks' cost-cutting and manufacturing scaling capabilities are being put to the test.

2 Top Biotech Stocks That Wall Street Thinks Could Soon Double in Value

SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.

Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024

Iovance Therapeutics (NASDAQ: IOVA ) — which specializes in novel cancer therapeutics — is seeing shares skyrocket more than 35% on Tuesday. A combination of regulatory approval and possible short-squeeze speculation is boosting IOVA stock today.

Why Is Iovance Therapeutics (IOVA) Stock Up 35% Today?

Shares of the biotechnology company are on pace for their best day since June 2016.

Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.

On Friday, the Food and Drug Administration granted accelerated approval to Amtagvi as a treatment for advanced melanoma. Iovance also announced the pricing of a secondary stock offering.

Why Iovance Biotherapeutics Stock Is Skyrocketing Today

Iovance Biotherapeutics Inc (NASDAQ:IOVA) stock is up 39.5% at $12.76 at last check, after the company received  accelerated approval  from the Food and Drug Administration (FDA) for its cell therapy for adults with advanced melanoma, which is priced at $515,000 per patient.

Iovance Stock Eyes Best Day Since 2020 After FDA Nod

AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. PHILADELPHIA , Feb. 20, 2024 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma

Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, named Amtagvi, for the treatment of advanced melanoma after anti-PD-1 and targeted therapy. Amtagvi has the potential to carve out a niche in the crowded melanoma treatment market, offering hope to patients with few options left.

Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma

SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (“Iovance” or “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Iovance, are expected to be approximately $211 million. The offering is expected to close on or about February 22, 2024, subject to customary closing conditions.

Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common Stock

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi

Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earnings report that is scheduled on Friday.

Iovance (IOVA) stock price could rocket higher ahead of earnings

The Food and Drug Administration approved a groundbreaking cellular treatment Friday for two types of advanced melanoma aimed at combating tumor growth in adult patients with the skin cancer who have already attempted other treatments, potentially transforming future treatment on advanced cancer tumors.

FDA Approves First Cellular Treatment For Advanced Melanoma

Iovance Biotherapeutics said on Friday the U.S. health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approved for the deadliest form of skin cancer.

US FDA grants accelerated approval for Iovance's skin cancer cell therapy

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024.

Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy

News for Iovance Biotherapeutics Stock (IOVA)